EIK1001
As of the edition of 20 October 2026, EIK1001 is a drug known only by a code name: in active development; acts on TLR7 and TLR8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eikon Therapeutics | Lead sponsor of trials | 2024 to now |